NCT04189211View on ClinicalTrials.gov

A Clinical Trial of BAT8001 on Safety, Tolerability and Pharmacokinetics for Patients

PHASE1UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 7, 2017

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2020

Conditions
HER2-Positive Solid Tumors
Interventions
DRUG

BAT8001

IV infusions.

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

Sponsors
All Listed Sponsors
lead

Bio-Thera Solutions

INDUSTRY